Neuroprotective effects of HTR1A antagonist WAY-100635 on scopolamine-induced delirium in rats and underlying molecular mechanisms by unknown




of HTR1A antagonist WAY-100635 
on scopolamine-induced delirium in rats 
and underlying molecular mechanisms
Yimin Qiu1*, Dongmei Chen1, Xiaojing Huang2, Lina Huang1, Liang Tang1, Jihong Jiang2, Lianhua Chen1 
and Shitong Li3
Abstract 
Background: Limited surveys have assessed the performance of 5-hydroxytreptamine receptor 1A and its antagonist 
WAY-100635 in pharmacological manipulations targeting delirium therapies. The purpose of this paper was to assess 
the central pharmacological activity of WAY-100635 in a rat model of scopolamine-induced delirium and its underly-
ing mechanism.
Results: A delirium rat model was established by intraperitoneal injection of scopolamine and behavioral changes 
evaluated through open field and elevated plus maze experiments. Concentrations of monoamines in the hip-
pocampus and amygdalae were detected by high performance liquid chromatography. The effect of WAY-100635 
on the recovery of rats from delirium was assessed by stereotactic injection of WAY-100635 and its mechanism of 
action determined by measuring mRNA and protein expression via real time PCR and western blotting methods. The 
total distance and the number of crossing and rearing in the elevated plus maze test and the time spent in the light 
compartment in the dark/light test of scopolamine-treated rats were significantly increased while the percentage of 
time spent in the open arms was decreased, showing the validity of the established delirium rat model. The measure-
ment of the concentrations of noradrenaline, 3,4-dihydroxyphenylacetic acid, the homovanillic acid, 5-hydroxy-3-in-
doleacetic acid and serotonin concentrations in the cerebrospinal fluid (CSF) of scopolamine-induced delirium rats 
were significantly increased. The intra-hippocampus and intra-BLA injections of WAY-100635 improved the delirium-
like behavior of rats by significantly reducing the expression of NLRP3 inflammasome and the release of IL1-β and IL8 
into CSF.
Conclusions: Taken together, these findings indicate that WAY-100635 may exert a therapeutic effect on post-
operative delirium by controlling neurotransmission as well as suppressing neuroinflammation in the central nervous 
system.
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Background
Delirium is a multi-factorial transient neuro-psychiat-
ric syndrome caused by well-defined predisposing and 
precipitating factors leading to severe outcome in hospi-
talized older patients [1]. Postoperative delirium (POD) 
is a common acute postoperative brain dysfunction that 
is associated with short-term complications such as an 
increase in mortality, morbidity, costs of medical care, 
poor functional recovery, postoperative cognitive dys-
function, deterioration in quality of life and length of stay, 
and long-term sequelae including persistent cognitive 
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deficits and loss of independence [2, 3]. The incidence 
of POD is variable depending on the type of surgical 
and anesthetic procedures [4]. For post-surgical elderly 
patients, the incidence of POD is up to 80 % [5–7] due to 
frequent cognitive impairments following general anes-
thesia and surgery. Although POD is ominously associ-
ated with poor outcomes in patients, partly or completely 
reversing the behavioral changes is still possible if we 
understand the nature of the causative factors and the 
associated physiopathology [8].
The physiopathology of delirium at molecular level 
is unclear. Nevertheless, the current knowledge sug-
gests that final common outcomes observed in POD are 
often associated with an alteration in neurotransmitter 
system that induces complex behavioral and cognitive 
changes [9]. Particularly, delirium results from dysfunc-
tions of multiple systems of cholinergic neurotransmit-
ters, which are characterized by significantly higher total 
serum anticholinergic activity (SAA) in older and young 
POD patients [10]. Central cholinergic pathways are 
involved in the control of cognitive processes which are 
responsible for the acquisition and retention of informa-
tion as well as task performances. The dysfunctions of 
these pathways, induced by pharmacological administra-
tion of anticholinergic agents such as atropine and sco-
polamine or excitotoxic lesions, can produce a variety of 
behavioral effects and cause delirium [6, 11]. In general, 
the most commonly described neurotransmitter changes 
associated with POD include excess release of dopamine, 
norepinephrine and/or glutamate, as well as variable 
alterations of serotonin (5-hydroxytryptamine, 5-HT), 
histamine, and/or γ-aminobutyric acid (GABA) [12, 13]. 
Notably, neurotransmitters such as acetylcholine and 
serotonin have been found to play remarkably impor-
tant functions in POD [14]. Nonetheless, the mecha-
nisms by which 5-HT (serotonin) contributes to specific 
symptomatology of delirium remain an intense topic of 
investigation. Emerging evidence points to a role for the 
5-hydroxytreptamine 1A (5-HT1A) receptor, which is 
highly expressed in limbic areas related to memory stor-
age such as hippocampus, in the expression of specific 
symptoms of delirium. As a result, much attention has 
been paid to the HTR1A because its activation in discrete 
brain regions appears to be a sufficient stimulus to elicit 
specific symptoms of delirium.
Currently, pharmacological intervention has been 
well documented to reduce the incidences and sever-
ity of POD [15], among which antipsychotics are of bet-
ter choice [5, 8]. However, the data to support specific 
pharmacological interventions for its treatment is still 
limited and current preventative strategies mainly con-
sist of aggressive management of known risk factors [16]. 
Interestingly, the highly selective HTR1A antagonist, 
WAY-100635 (N-[2-(4-(2methoxyphenyl)-1-piperazinyl) 
ethyl]-N-(2-pyridinyl) cyclohexane carboxamide), has 
shown ability to block all of the effects induced by stimu-
lation of this 5-HT receptor subtype [17, 18]. Therefore, 
studying the pharmacological effect of WAY-100635 in 
delirium could be valuable for therapeutic purposes.
Furthermore, a certain number of studies provided 
novel evidence that CNS (central nervous system) 
inflammation involving levels of cytokines such as IL-1β, 
IL-6 and IL-8 and pro-inflammatory molecules such as 
interferon gamma (IFN-γ) and anti-inflammatory mol-
ecules including insulin-like growth factor 1 (IGF-1) and 
IL-1ra may be associated with pathogenesis of delirium. 
Previous investigations showed that some important 
brain regions, including frontal lobes, diencephalon, hip-
pocampus, amygdala and cerebellum define executive 
function, memory, attention, and play an important role 
in pathogenesis of delirium [19]. Despite abundant litera-
ture indicating the presence of monoamine transmitters 
in most brain regions that contain serotonergic neurons, 
little is known about their possible relationship with 
delirium symptoms and neuro-inflammation systems. 
Therefore, the neuropathogenesis for delirium, espe-
cially POD, remains largely to be determined through 
the establishment of animal models using cholinergic 
antagonists such scopolamine [20–22]. In addition, fewer 
attempts have been made to determine the expression 
of memory-related molecules in different brain regions 
of scopolamine-treated animals. Unearthing molecular 
mechanisms associated with delirium could enable the 
development of therapies due to better understanding of 
signaling pathways in play.
The main objective of the current pilot studies was to 
evaluate the ability of scopolamine to induce a delirium-
like state in rats, to investigate changes in monoamine 
levels in different brain regions (including hippocampus 
and amygdala), and to determine whether rat behavioral 




Healthy 2-month-old male SD rats, weighing 140–160 g 
were provided by the Second Military Medical University 
Animal Center (Shanghai, China) and housed in groups 
of three under controlled environment [18–20 °C, relative 
humidity of 55 ± 10 %, 12 h light/dark cycle (7:00 A.M. to 
7:00 P.M.)] with free access to food and water. The main-
tenance and handling of the rats were performed in line 
with the Guide of Shanghai General Hospital for the Care 
and Use of Laboratory Animals. The study was reviewed 
and approved by the review board of the Shanghai Gen-
eral Hospital Animal Care and Use Ethics Committee. 
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Each experiment occurred between 14:00 and 17:00 in 
order to avoid interferences of central neurotransmitter 
release caused by circadian rhythm. All measures were 
taken to reduce pain and the number of rats used in the 
study.
Establishment of scopolamine‑induced delirium rat model
A rat model of delirium was established via induction 
by intraperitoneal injection of different doses of sco-
polamine into rats according to their body weight. SD 
rats (n = 90) were randomly divided into control group 
(n  =  15), saline group (n  =  15) and four scopolamine 
treatment groups (n =  15 for each group) according to 
the concentration of scopolamine injected. The scopola-
mine concentrations tested were 0  mg/kg (control and 
saline groups), 0.3, 0.9, 1.2 and 1.8  mg/kg. Rats in the 
saline group were intraperitoneally infused with 1  ml 
physiological saline solution as vehicle. Thereafter, behav-
ioral tests were performed to confirm memory impair-
ment in rats.
Monitoring and analysis of behavior
The tests used to assess the behavior of the rats included 
the open field test,the elevated plus-maze test of anxi-
ety and the light/dark test which were performed as 
described below.
Open field test
The open field experiment was done as described 
elsewhere [23] using a self-made open-field test box 
(100  cm  ×  100  cm  ×  50  cm) uniquely made of Plexi-
glas with the base surface divided into 25 squares of 
20 cm × 20 cm. The test was performed under dim light 
(40 W) in order to decrease the anxiety of the rats. Prior 
to test, the rats were weighed and gently put into the 
open field test chamber to get familiarized with the envi-
ronment for 30  min to 1  h. After that, rats were gently 
and individually placed into the center of the open-field 
test box and were permitted free movement for 1 h. The 
movement parameters of each normal, scopolamine or 
saline solution injected rat were monitored and analyzed 
via a video-tracking system (Shanghai Mobile Datum 
Information Technology Company, Shanghai, China) 
each 5 min. The test box was cleaned after the removal 
of each animal in order to avoid that the remaining infor-
mation of previous animals affects the next test results.
Elevated plus‑maze test of anxiety
The maze was performed as described elsewhere [24]. 
The plus-maze apparatus consisted of two open arms, 
50 × 10 cm, and two enclosed arms, 50 × 10 × 40 cm. 
Two arms were enclosed on three sides by 9  cm high 
transparent perspex and the other two arms were open. 
The rats were placed in the center of the lit looking the 
open arm and were assessed in a 5-min session. The rats 
behavior was recorded (Shanghai Mobile Datum Infor-
mation Technology Company, Shanghai, China) and 
scored as the time spent by the rats in the closed and 
open arms. An arm entry was defined as two paws having 
crossed the dividing line between an arm and the central 
area.
Light/dark test
Immediately after the open-field test, all animals were 
submitted to the light/dark test using a rectangular Plexi-
glas box (44 × 8.5 × 25 cm) divided into light and dark 
sections that were separated by a door. Each rat was indi-
vidually placed in the middle of the light compartment 
for 10 s exploration, after which, the way to the dim com-
partment was opened. The time spent in the dark and 
light compartments, the number of transitions, and the 
latency to enter the dark compartment were measured 
during a 10 min session.
Measurement of the concentrations of monoamine 
neurotransmitters
Anesthesia, surgery and collection of rat cervical 
cerebrospinal fluid samples
After behavioral test, rats were put under anesthesia by 
intraperitoneal injection of pentobarbital (35  mg/kg). 
After anesthesia, a rat was placed in the horizontal posi-
tion on a test table. The most caudal interspinous space 
was identified as a tactile landmark at the L3/L4 lumbar 
segment. After alcohol disinfection and shaving, a mid-
line skin incision, approximately 2  cm in length, was 
made to expose the interspinous space at L3/L4 lumbar 
segment. After careful removal of the L3/L4 interspinous 
ligament, a metal needle was used for perforating the 
dural sac. A PP catheter was inserted at the junction of 
neck and chest cone segment from the dural tear to suba-
rachnoid cephalic. After discarding the first 20  μl cer-
ebrospinal fluid of each rat, 50  μl of cerebrospinal fluid 
was collected for the blank control group. After intraperi-
toneal injection of scopolamine or saline solution, 50 μl 
of cerebrospinal fluid was collected at specific periods 
(5–10, 15–20, 25–30 and 55–60 min) in an ice bath under 
dark conditions. Thereafter, the specimens were collected 
by centrifugation and immediately stored at −80 °C.
Microdialysis and HPLC analysis of monoamine 
neurotransmitters
Sample pre-treatment and detailed detection method 
were as previously described [25]. The concentrations of 
monoamine neurotransmitters including Norepinephrine 
(NE), 3,4-dihydroxyphenylacetic acid (DOPAC), homo-
vanillic acid (HVA), 5-hydroxyindolacetic acid (5-HIAA), 
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5-hydroxytryptamine (5-HT), acetylcholine (Ach) and 
dopamine (DA) were quantified by HPLC analysis which 
was performed on an ESA (Chelmsford, MA) CoulArray 
HPLC instrument equipped with CouloChem III dual 
channel electrochemical detector channels utilizing an 
ESA 5041 carbon electrode. EZChrom software installed 
on a 32-bit PC was used for signal acquisition and data 
analysis and processing. The Capcell-MG2-C18 reverse 
column (150X2  mm, 3  µm) and a C-18 guard column 
were used for elution at a flow rate of 0.3 ml/min using 
a mobile phase containing 50  mM citric acid, 100  mM 
disodium hydrogen phosphate, 50 uM/L EDTA-2Na 
and 60 mg/L OAS, 6 % methanol. The mobile phase was 
unrecyclable, freshly prepared and filtered using a 0.45 
um membrane. Quantitative analysis was accomplished 
using calibration curves obtained with standards of NE, 
DA, HVA, DOPAC, 5-HT, Ach, dopamine and 5-HIAA 
purchased from Sigma-Aldrich (Milwaukee, WI). Stand-
ard curves were established on the day of the experi-
ment to ensure accuracy. The applied voltage was set to 
350 mV and the guard electrode voltage was 400 mV with 
intensity of 50 uA. The analytical column and the elec-
trode temperature was set to 32  °C using a single pump 
or the gradient-like mode analysis.
Pharmacological effect of WAY‑100635 on rat delirium
Animal grouping
SD rats were divided into 5 groups: scopolamine delirium 
group (model, n =  20), saline group (n =  20), scopola-
mine delirium group + WAY-100635 (model treated with 
WAY-100635, n  =  40, 20 rats for hippocampus stud-
ies and 20 for amygdala studies), saline +  WAY-100635 
group (saline rats treated with WAY-100635, n  =  40, 
20 rats for hippocampus studies and 20 for amygdala 
studies) and WAY-100635 group (normal rats treated 
uniquely with WAY-100635, n  =  40, 20 rats for hip-
pocampus studies and 20 for amygdala studies).
Surgical procedure
Before surgery, rats were anesthetized with 35  mg/kg 
pentobarbital anesthesia according to the rat weight. 
These animals were implanted bilaterally with stain-
less-steel guide cannulae (11 mm) aimed above the hip-
pocampus or BLA. The coordinates were determined 
by the rat brain atlas: for hippocampus, anteroposte-
rior (AP), −3.4  mm from bregma, mediolateral (ML), 
−1.7  mm from midline, dorsoventral (DV), −2.7  mm 
from skull surface; for BLA, AAP  =  2.8  mm caudal to 
bregma, Lat = 4.6 mm lateral to midline, DV = 8.7 mm 
ventral from the skull surface. The cannulae were affixed 
to the skull with dental cement, while two anchoring sur-
gical screws and insect pins were inserted into the cannu-
lae to maintain patency. After the cement was completely 
desiccated and solidified, two stainless steel stylets 
were employed for occluding the guide cannulae in the 
recovery period. Animals were individually housed and 
allowed to recover for 5–7 days before testing.
Drug microinjections
Microinjections of WAY-100635 purchased from Sigma 
(St Louis, MO, USA) were made 15 min prior to behav-
ioral testing. During microinjections, rats were gently 
restrained by hand. After the stylets were removed from 
the guide cannulae by lowering stainless steel injector 
cannulae (30-G needle) with a length of 2  mm longer 
than the guide cannulae, microinjections were sepa-
rately performed into either ventral hippocampus or BLA 
according to the animal grouping. Preliminary studies 
of injection of different concentrations of WAY-100635 
solution (0.02, 0.05, 0.1, 0.2 mg/kg) were carried out on 
a limited number of rats to find out the optimal concen-
tration of WAY-100635 to be administered. On this basis, 
WAY-100635 solution (0.1  mg/kg) was administered 
slowly in a total volume of 2.0 μl into the hippocampus 
and BLA over 60 s. Injection needles were left in place for 
an additional 60 s, followed by reinsertion of the stylets 
into the guide cannulae. All microinjections were per-
formed bilaterally.
Behavioral test
After microinjections of WAY-100635, the open field test, 
the elevated plus-maze test of anxiety and the light/dark 
test were performed as described above.
Preparation of tissue lysates
For gene and protein expression analysis, rats were sacri-
ficed by decapitation 2 h after injection of WAY-100635. 
After decapitation the brains were removed and imme-
diately frozen on dry ice before dissection. To prepare 
tissue lysates, the prefrontal cortex (comprising motor 
cortex (areas 1 and 2) and cingulated cortex), striatum 
(dorsal), amygdala and hippocampus (caudal) were dis-
sected and homogenized in 5 volumes of ice-cold buffer 
containing 50 mm Tris–HCl (pH 7.7), 150 mm NaCl, 1 % 
Nonidet P-40, 2 mm EDTA, 0.25 % sodium deoxycholate 
(DOC), 2 mm EGTA, 0.5 mm phenylmethylsulfonyl fluo-
ride, 10 µg/ml leupeptin and incubated on ice for 30 min. 
After centrifugation at 14,000g for 20 min of the homoge-
nate, the supernatant (tissue lysate) was aliquoted and 
congealed at −80 °C.
Western blotting
Lysates of hippocampus and BLA were heated at 80  °C 
for 30 min in RIPA buffer, and then centrifuged for 5 min 
at 10,000g. 20  µg total proteins was electrophoresed in 
a 10  % SDS-PAGE gel, and then electrically transferred 
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onto PVDF membranes using a semidry method. The 
membranes were blocked for 1 h with a solution of TBS 
[containing 5 % (w/v) fat-free milk, and 0.5 % Tween 20], 
followed by overnight incubation at 1:1000 dilution at 
4 °C with the following primary antibodies: anti-5HT1A 
receptor antibody (ab121032), Anti-5HT1B recep-
tor antibody (ab85937), anti-5HT7 receptor antibody 
[EPR6271] (ab128892), anti-5HT3B receptor antibody 
(ab39629), anti-NLRP3 antibody (ab98151), anti-AKT1 
(phospho S473) antibody (ab66138), anti-PI3K p85 
(phospho Y607) antibody (ab182651), phosphor-S6K 
antibody, anti-muscarinic acetylcholine receptor 1 anti-
body (ab77098), anti-nicotinic acetylcholine receptor 
alpha 1 antibody (ab28489), anti-dopamine receptor D1 
antibody (ab20066) and anti-GAPDH antibodies (all anti-
bodies were purchased from Santa Cruz). GAPDH was 
used as endogenous reference for proteins. Thereafter, 
membranes were washed four times with PBS, and incu-
bated with horseradish (HRP)-conjugated peroxidase 
anti-rabbit IgG (dilution 1:5000) for 1  h at room tem-
perature. Detection was performed using the ECL-plus 
enhanced chemiluminescence system (ECL Amersham 
Biosciences) after autoradiographic exposure to Hyper-
filmTM.ECL (Amersham Biosciences). The program 
ImageMaster I-D (Pharmacia, Sweden) was used for 
quantitative determination of signals by densitometry.
Real time‑PCR
Quantitative real-time PCR was used for detecting the 
mRNA expression level of 5-HT1A at gene level. Trizol 
extraction kit (Invitrogen, Carlsbad, CA) was employed 
for extracting total RNA from lysates of the frontal lobes, 
diencephalon, hippocampus, amygdale, parietal cortex and 
cerebellum. Subsequently, 1.5 μg extracted total RNA was 
converted into cDNA using First-Strand Synthesis System 
for RT-PCR (Invitrogen). The qRT-PCR experiment was 
achieved with the QuantiFast SYBR Green PCR Kit (Qia-
gen, Germany) according to the manufacturer’s protocol 
using a reaction volume of 20 μl. The PCR cycling condi-
tion was set as follows: 95 °C for 5 min, 40 cycles of 95 °C 
for 15 s, 60 °C for 15 s and 72 °C for 20 s. The fluorescence 
intensity was determined by the Bio-Rad CFX96™ Real-
Time System. The relative levels of mRNA for the above 
receptor genes and 5-HT gene were normalized to GAPDH 
which was used as an endogenous gene. The primers used 
are presented in Table 1. Each test was run in triplicate.
Determination of IL‑1β, IL‑8 and TNF‑α levels in CSF
IL-1β, IL-8 and TNF-α were quantified by sandwich 
ELISA using an IL-1β/IL-1F2 (R&D Systems, IL-1β/
IL-1F2 Quantikine ELISA Kit), IL-8 and TNF-α (Bio-
Source, Camarillo, CA) ELISA kits according to manu-
facturers’ guidelines.
Statistical analysis
Data are presented as mean ± SD. GraphPad Prism ver-
sion 5 was used to generate the graphics and perform 
statistical analysis. Groups were compared using one-
way ANOVA followed by Bonferroni post tests for inter-
group comparisons. Statistical significance was assigned 
to p values less than 0.05.
Results
Behavioral changes in scopolamine‑induced delirium 
model
In open field test, locomotor activity was quantified in 
terms of total distance traveled after treatment with var-
ied concentrations of scopolamine. Scopolamine treat-
ment of 0.3 and 0.9 mg/kg did not elicit any differences in 
the total distance traveled relative to normal and control 
vehicle rats (Fig. 1a). Similarly, treatment with high sco-
polamine concentration led to significant increase of the 
number of crossing and the number of rearing compared 
to those of normal and saline-treated (1.0  ml/kg) rats. 
In elevated plus maze test, the percentage of time spent 
in the open arms of rats treated with 1.8 mg/kg was sig-
nificantly decreased compared with saline-treated groups 
(F = 13.82, p < 0.001; Fig. 1d). As shown in Table 2, rats 
infused with 1.8 mg/kg scopolamine spent more time and 
ran long distances in the light compartment of the light/
dark box compared to normal, saline and rats treated 
with low doses of scopolamine. Scopolamine treatment 
did not affect the number of transitions into the different 
compartments.
Concentration of neurotransmitters in the cerebrospinal 
fluid (CSF) and brain regions of rats
The concentrations of NE, Dopamine (DA), DOPAC, 
HVA, 5-HIAA, 5-HT and acetylcholine (Ach) in the 
CSF of scopolamine-induced impairment rats were 
Table 1 Primers used for real time PCR experiments
Gene Primers
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312.61 ± 22.24, 200.50 ± 53, 151.15 ± 18.93, 42.03 ± 5.98, 
337.83 ± 80.31, 472.80 ± 52.92 and 75 ± 2 pg/μl, respec-
tively, and were significantly increased compared to those 
of normal and saline-treated rats (Fig. 2a).
 Because it was reported that delirium is associ-
ated with brain regions that play an important role in 
executive functions (e.g., frontal lobes, diencephalon), 
memory (e.g., hippocampus, BLA), and attention (e.g., 
parietal cortex, cerebellum) [19], neurotransmitters 
including NE, DOPAC, HVA, 5-HIAA and 5-HT1A in 
hippocampus, amygdala, prefrontal cortex and striatum 
were measured. Compared to saline-treated rats, we 
Fig. 1 Scopolamine-induced delirium-like behavior of rats. a Number of crossing, b number of rearing and c total distance moved during the 
5 min session in the open field test. d Percentage of time spent in the open arms during the 5 min session in the elevated plus maze test. Data are 
presented as mean ± SD. ***p < 0.001 by comparison against saline and control groups, N.S not significant
Table 2 Effects (mean ± SEM) of scopolamine rats in the light–dark transition model (n = 20 animals/group)
Time spent (s) Total distance moved (cm) Number 
of transi‑
tionsLight Dark Light Dark
Normal 140 ± 8.5 520 ± 7.45 1400 ± 304 2400 ± 235 9.7 ± 0.45
Saline 140 ± 7 528 ± 7.45 1350 ± 132 2340 ± 234 10.05 ± 0.75
Scopolamine treatment (mg/Kg)
 0.3 275.7 ± 10. 190 ± 8.5 1269 ± 200 2154 ± 159 9.2 ± 1.2
 0.9 283 ± 3.5 182 ± 8.5 2000 ± 304 1564 ± 144 9.55 ± 0.5
 1.2 350.9 ± 15 1790 ± 7 2150 ± 132 1812 ± 128 9.5 ± 1.5
 1.8 409 ± 6.3 183 ± 10.32 2252 ± 150 1765 ± 235 9.01 ± 0.6
Page 7 of 12Qiu et al. BMC Neurosci  (2016) 17:66 
found that scopolamine treatment significantly promoted 
the release of NE (p  <  0.01; Fig.  2b), HVA (p  <  0.01; 
Fig. 2c) and 5-HT (p < 0.001; Fig. 2d) in the hippocam-
pus and BLA of high dose scopolamine-treated rats while 
no significant changes were recorded in the prefrontal 
cortex and the striatum. The concentration of 5-HIAA 
(p < 0.001; Fig. 2e) was increased in BLA but not in hip-
pocampus while DA and DOPAC (p  <  0.001; Fig.  2f ) 
were increased in hippocampus but not in BLA. Mean-
while, the increased extent of 5-HT was higher than that 
of HVA, NE and DOPAC, especially in hippocampus of 
scopolamine-treated rats. The concentrations of DA, 
DOPAC, HVA and Ach were significantly higher in the 
prefrontal cortex and striatum compared to the amygdala 
while lower concentrations of NE, 5-HT and 5-HIAA 
were found in these regions. No significant differences 
were recorded between prefrontal cortex and striatum 
or between normal, saline or scopolamine treated rats in 
these regions.
Activation of HTR1A in hippocampus and amygdala 
mediates the anxiogenic effect of scopolamine
Based on scopolamine-induced increase of 5-HT in CSF, 
levels of 5-hydroxytryptamine receptor 3B (HTR3B), 
5-hydroxytryptamine receptor 7 (HTR7), cholinergic 
receptor nicotinic alpha 4 subunit (CHRNA4), dopa-
mine receptor D1 (DRD1), muscarinic acetylcholine 
receptor M1 (CHRM1), 5-hydroxytryptamine recep-
tor 1B (HTR1B) and 5-hydroxytryptamine receptor 1A 
(HTR1A) were investigated in brain regions such as hip-
pocampus, amygdala, prefrontal cortex and striatum. The 
result showed that for control rats with saline treatment 
or scopolamine-induced delirium rats, the protein level 
(Fig. 3a, b) and mRNA level (Fig. 3c) of HTR1A were sig-
nificantly higher in hippocampus and BLA than other 
brain regions. Meanwhile, the expression of HTR1A in 
hippocampus and BLA of scopolamine-induced delirium 
rats was significantly increased when compared with 
those of saline-treated rats. The expression of HTR1B 
receptor was slightly increased in the four studied brain 
regions when compared with the saline treated rats, but 
no significant differences were recorded between groups 
or brain regions. Scopolamine treatment did not signifi-
cantly affect the expression of HTR3B, HTR7, CHRNA4, 
DRD1 and CHRM1. These results indicate that the effect 
of scopolamine on memory impairment may be spe-
cifically mediated by high expression of HTR1A in hip-
pocampus and amygdala.
Fig. 2 Effects of scopolamine on neurotransmitters in CSF and different delirium-associated brain regions. a The concentrations of neurotransmit-
ters including NE, HVA, 5-HT, 5-HIAA, DA, DOPAC and Ach were determined in the CSF of normal, saline and scopolamine treated-rats. NE (b), HVA 
(c), 5-HT (d), 5-HIAA (e), DA (f), DOPAC (g) and Ach (h) were equally measured in hippocampus, amygdala, prefrontal cortex and striatum tissue 
homogenates by HPLC. Each value represents the mean ± SD of the parameters recorded, and the statistical analysis by Bonferroni’s test following 
one way ANOVA. ***p < 0.001 by comparison against indicated groups, N.S not significant
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Effects of WAY‑100635 on behavioral performance 
and biochemical phenotypes of scopolamine‑induced 
memory impairment rats
Based on above results, stereotactic intra-hippocampus 
and intra–BLA injections of the HTR1A antagonist, 
WAY-100635, were performed in scopolamine-treated 
rats. Compared to scopolamine treatment, the micro-
injection of WAY-100635 (0.1  mg/Kg) to the delirium 
model group improved the number of crossing (p < 0.05; 
Fig. 4a), the number of rearing (p < 0.05; Fig. 4b) and the 
total distance (p < 0.05; Fig. 4c) in the open field test. In 
elevated plus maze test, the percentage of time spent in 
the open arms by the model group treated with WAY-
100635 was significantly increased as compared with 
model groups (p < 0.05; Fig. 4d). Furthermore, we tested 
the effect of WAY-100635 in the light/dark test. Con-
trary to high dose scopolamine-treated rats, we recorded 
significant increase in total distance moved and in the 
number of entries in the dark compartment (Fig. 4e) and 
significant decrease in the time spent in the light com-
partment after WAY-100635 treatment were observed 
(p < 0.05; Fig. 4f ). We equally tested the effect of WAY-
100635 on the biochemical phenotypes and found that 
(Fig. 5) treatment of rats with WAY-100635 reversed the 
concentration of neurotransmitters in the hippocam-
pus and amygdala of rats of delirium rats (1.8  mg/kg 
scopolamine).
Effects of WAY‑100635 on the expressions of cytokines 
and PI3K/Akt/mTOR pathway proteins
Based on the association of neuroinflammation with 
delirium [26, 27], the levels of IL-1β, IL-8 and TNF-α in 
CSF were measured before and after WAY-100635 treat-
ment. Intriguingly, it was found that the release of IL-1β 
and IL-8 into CSF was decreased after WAY-100635 
treatment (Fig.  6a) while the levels of TNF-α were not 
significantly affected by WAY-100635 treatment. Accu-
mulating data demonstrate that the release of IL-1β in 
CNS is induced by the activation of intercellular cas-
pase-1, which is regulated by the NLRP3 inflamasome 
[28]. Therefore, the expression of NLRP3 in hippocampus 
and BLA tissue homogenates was measured after WAY-
100635 treatment. The result (Fig.  6b, c) showed that, 
compared with that in hippocampus and BLA of scopol-
amine-induced delirium rats, expression of NLRP3 in 
such two brain regions was decreased after WAY-100635 
treatment. Meanwhile, it was also found that phosphor-
AKT (Ser473), phosphor-PI3K (p85α) and phosphor-
S6K level were decreased after WAY-100635 treatment 
(Fig. 6c–i).
Discussion
In humans, anticholinergic agents such as scopolamine 
are known to produce delirium-like states in patients 
and experimental animals [29–33]. For this reason, a 
Fig. 3 Expression of neurotransmitter receptors in different delirium-associated brain regions of control rats before and after scopolamine treat-
ment. a Protein levels of neurotransmitter receptors were detected by western blot, b quantitative analysis of blots by densitometry, c mRNA level 
of neurotransmitters determined by qPCR; ***p < 0.001 by comparison against other neurotransmitter receptors
Page 9 of 12Qiu et al. BMC Neurosci  (2016) 17:66 
scopolamine-induced delirium rat model was established 
in this report by intraperitoneal injection of 1.8 mg/kg of 
scopolamine in order to assess the delirium-related psy-
chological behaviors. The results revealed the increase of 
crossing and rearing, and the decrease of the percentage 
of time spent in the open arms by scopolamine-treated 
rats comparatively to control rats treated with saline solu-
tion. In addition, the light/dark test revealed that after 
injection of 1.8 mg/Kg scopolamine, the distance moved 
and time spent in light compartment were increased 
while the transition between both light and dark com-
partment did not significantly changed. These observa-
tions potentiate the scopolamine-induced delirium rats 
as a useful delirium model for studying impairments of 
psychological behaviors and corroborated with the find-
ings of K Nakamura, M Kurasawa and Y Tanaka [34] who 
showed that the intraperitoneal injection of 0.3  mg/kg 
of scopolamine engendered an impairment of task per-
formance, increase in percent omission and decrease in 
percent correct, demonstrating behavioral discrepancies 
and a reduced arousal or vigilance.
Nowadays, it is believed that CSF analysis in search 
of the pathogenesis of delirium has great potential to 
advance understanding of POD pathophysiology due 
to its proximity to the brain and its immune-privileged 
position behind the blood brain barrier (BBB) [26]. In 
order to investigate the effect of scopolamine on the 
expression of neurotransmitters, we performed HPLC 
analysis of the CSF and found that NE, DOPAC, HVA, 
5-HIAA and 5-HT concentrations in CSF of scopola-
mine-induced delirium rats were significantly increased, 
with a particular emphasis for 5-HT. For providing con-
sistent data of these neurotranmitters on delirium, we 
further studied the release of some neurotransmitters 
in hippocampus and BLA. The release of NE, HVA and 
5-HT in hippocampus and BLA of scopolamine-induced 
delirium rats increased considerably by comparison 
with the control group. 5-HIAA was increased in BLA 
Fig. 4 WAY-100635 reversed scopolamine-induced delirium-like behavior of rats. a Number of crossings, b number of rearing and c total distance 
moved during the 5 min session in the open field test, d Percentage of time spent in the open arms during the 5 min session in the elevated plus 
maze test, e total distance moved during the 10 min session in the light/dark test, f time spent in the open arms during the 10 min session in the 
light/dark test. Data are presented as mean ± SD. ***p < 0.001 by comparison against control rats and #p < 0.001 by comparison against scopola-
mine-treated rats
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but not in hippocampus while quite the opposite was 
recorded for DOPAC. In addition, the increased extent 
of 5-HT was higher than that of other neurotransmit-
ters, especially in the hippocampus. These results are 
consistent with previous findings suggesting that hip-
pocampus is selectively enmeshed in contextual memory 
consolidation while the amygdala is mostly engaged in 
modulating the consolidation of memory for emotionally 
Fig. 5 Effects of WAY-100635 on neurotransmitters in hippocampus and amygdala of delirium rats. The concentrations of neurotransmitters includ-
ing NE (a), HVA (b), 5-HT (c), 5-HIAA (d), DA (e), DOPAC (f) and Ach (g) were equally measured in hippocampus, amygdala, prefrontal cortex and 
striatum tissue homogenates by HPLC. Each value represents the mean ± SD of the parameters recorded, and the statistical analysis by Bonferroni’s 
test following one way ANOVA. ***p < 0.001 by comparison against indicated groups, N.S not significant
Fig. 6 Effects of WAY-100635 treatment on cytokine release into CSF, NLRP3 expression and signaling pathways activation in hippocampus and 
BLA. a ELISA analysis of cytokine release into CSF of control, scopolamine-treated and WAY-100635 treatment groups. b Western blotting analysis 
of NLRP3 expression and phosphorylated PI3K [phosphor-PI3K (p85α)], AKT [phosphor-AKT (Ser473)] and S6K [phosphor-S6K] and GAPDH in hip-
pocampus and BLA from different groups rats. c–i Quantitative values of western blot analysis. a: Saline, b: Saline + WAY-100635, c: scopolamine, d 
scopolamine + WAY-100635, e: normal + WAY-100635. ***p < 0.001 by comparison against other groups
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arousing experiences [35]. The present results equally 
support an association between higher level of 5-HT in 
CSF and delirium, indicating that more definitive studies 
of the relationship between 5-HT level and delirium are 
now required [36]. In addition, in the two brain regions, 
increase of mRNA and protein levels of HTR1A was 
discovered in the present study. This novel finding indi-
cates that serotonergic neurotransmissions located on 
hippocampus and amygdale function in controlling the 
pathogenesis of delirium [37], implying that antagonism 
at 5-HT receptors must be an important tool in treating 
delirium as it was previously demonstrated for 5-HT2 
receptors [38]. To verify this hypothesis, we proceeded to 
microinjections of WAY-100635, a potent and selective 
HTR1A antagonist, into the hippocampus and BLA of 
scopolamine-treated rats. It was observed that, compared 
to control rats, treatment of WAY-100635 improved the 
delirium-like behavior of rats. As discussed above, the 
serotonergic system may vary depending on the severity 
of delirium symptoms, but HTR1A antagonist treatment 
affecting the function of hippocampus can influence the 
modulation of a variety of neurophysiological changes 
[38].
Furthermore, previous researchers indicated that cho-
linergic system and inflammation are common pathways 
involved in delirium pathophysiology and incriminated 
IL-1β as the major inflammatory factor [26, 27]. In order 
to investigate the possible connection of WAY-100635 
with inflammatory pathways in the occurrence of delir-
ium, a key pro-inflammatory cytokine IL-1β in CSF was 
analyzed before and after WAY-100635 treatment. It was 
observed that release of IL-1β into CSF was decreased 
after WAY-100635 treatment. In addition, the NLR fam-
ily, pyrin domain-containing 3 (NLRP3) inflammasome, 
an important upstream regulator of IL-1β, and phosphor-
AKT (Ser473), phosphor-PI3K (p85α) and phosphor-
S6K expressions were decreased. These results implied 
that WAY-100635 improves the rat delirium systems by 
inhibiting the PI3K/AKT/mTOR activation in hippocam-
pus and BLA to subsequently prevent NLRP3-mediated 
IL-1β release into CSF. Consistent with previous find-
ings, this study approves that the PI3K/Akt signal path-
way may be involved in both the non-spatial and spatial 
cognitive impairment and its reversal using WAY-100635 
may be useful in alleviating delirium symptoms.
Conclusions
Taken together, the present findings indicate that cen-
tral nervous system serotonergic neuronal activity and 
neuro-inflammation in hippocampus and BLA could be 
involved in the pathogenesis of scopolamine-induced 
delirium model of rats, which may be important to 
understand the behavioral pathologies of delirium. 
Meanwhile, these data yield a novel insight that WAY-
100635, the selective antagonist of HTR1A could be clini-
cally useful in the ultimate treatment of POD.
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